IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Cappuzzo, F.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H. J.; Kopp, H-G.; Daniel, D.; McCune, S.; Mekhail, T.; Zer, A.; Reinmuth, N.; Sadiq, A.; Archer, V.; Lohmann, T. Ochi; Wang, L.; Kowanetz, M.; Lin, W.; Sandler, A.; West, H.

authors

Publication Date

  • October 1, 2018

webpage

published in

category

start page

  • 742

end page

  • +

volume

  • 29